The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Ceftriaxone Once Daily for Four Weeks Compared with Ceftriaxone Plus Gentamicin Once Daily for Two Weeks for Treatment of Endocarditis Due to Penicillin-Susceptible Streptococci
Abstract
This randomized, multicenter, open-label study compared the efficacy and safety of monotherapy with 2 g of intravenous ceftriaxone once daily for 4 weeks with those of combination therapy with 2 g of intravenous ceftriaxone and 3 mg of intravenous gentamicin/kg once daily for 2 weeks as therapy for endocarditis due to penicillin-susceptible streptococci. Sixty-one patients were enrolled in the study. Clinical cure was observed for 51 evaluable patients both at termination of therapy and at the 3-month follow-up: 25 (96.2%) of 26 monotherapy recipients and 24 (96%) of 25 combination therapy recipients. Of the 23 patients in each treatment group who were microbiologically evaluable, 22 (95.7%) in each group were considered cured. No patient had evidence of relapse. Fourteen patients (27.5%) required cardiac surgery after initiation of treatment, including five monotherapy recipients and nine combination therapy recipients. Adverse effects were minimal in both treatment groups. We conclude that 2 g of ceftriaxone once daily for 4 weeks and 2 g of ceftriaxone in combination with 3 mg of gentamicin/kg once daily for 2 weeks are both effective and safe for the treatment of streptococcal endocarditis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Durack, D. T., Lukes, A. S., Bright, D. K., & Service, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90143-0 · Cited by 2,572
Self-citationWilson, W. R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530210060032 · Cited by 492
Self-citationBrogden, R. N., Heel, R. C., Speight, T. M., & Avery, G. S. (1979) · Drugs · doi:10.2165/00003495-197917040-00001 · Cited by 311
Doern, G. V., Ferraro, M. J., Brueggemann, A. B., & Ruoff, K. L. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.891 · Cited by 294
Francioli, P., Ruch, W., Stamboulian, D., & International Infective Endocarditis Study Group (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.6.1406 · Cited by 147
Pharmacokinetic profile of ceftriaxone in man.
Patel, I. H., & Kaplan, S. A. (1984) · PubMed · Cited by 128
Antibiotic Management of Outpatients with Endocarditis Due to Penicillin-Susceptible Streptococci
Stamboulián, D., Bonvehí, P., Arévalo, C. E., Bologna, R., Cassetti, I., Scilingo, V. M., & Efrón, E. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.supplement_2.s160 · Cited by 126
Once-Daily Administration of Aminoglycosides
Bates, R. D., & Nahata, M. C. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800614 · Cited by 55
Single Daily Dosing of Aminoglycosides
Preston, S. L., & Briceland, L. L. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb04368.x · Cited by 51
Bayer, A. S. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.2.303 · Cited by 33
Research works printed but not linked: 4
- Etienne J, 1989, Pennsylvania: National Comtherapy, 35, 9
- Doern GV, 1996, Antimicrob Agents Chemother, 40, 4
- Patel IH, 1984, J Med, 19, 25
- Richards DM, 1994, Am J Hosp Pharm, 57, 21
Cited by
Sorted by citations
2015 ESC Guidelines for the management of infective endocarditis
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J., Zotti, F. D., Dulgheru, R., Khoury, G. A. E., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 5,086
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationPrevention of Infective Endocarditis
Wilson, W. R., Taubert, K. A., Gewitz, M. H., Lockhart, P. B., Baddour, L. M., Levison, M. E., Bolger, A. F., Cabell, C. H., Takahashi, M., Baltimore, R. S., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.183095 · Cited by 2,807
Self-citationGuidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer, Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., de Jesus Antunes, M., Thilen, U., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp285 · Cited by 2,014
2023 ESC Guidelines for the management of endocarditis
Delgado, V., Marsan, N. A., de Waha, S., Bonaros, N. E., Brida, M., Burri, H., Caselli, S., Doenst, T., Éderhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 2,039
Self-citation
Metadata
- Authors
- Sexton, D. J., Tenenbaum, M. J., Wilson, W. R., Steckelberg, J. M., Tice, A. D., Gilbert, D., Dismukes, W., Drew, R. H., Durack, D. T., & Endocarditis Treatment Consortium Group
- Affiliations
- Duke Medical Center (US)
- Mayo Clinic (US)
- Corresponding author
- Sexton, Daniel J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-12-01
- Volume
- 27
- Issue
- 6
- Pages
- 1470-1474
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1976043895
- Semantic Scholar
- 048ac2cb5b05b0d8ad8cedd6c53ecd0245719ee6
- Cited by
- 195
- References
- 16
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 5 · 2023: 9 · 2022: 1 · 2021: 2 · 2020: 8 · 2019: 5 · 2018: 4 · 2017: 2 · 2016: 4 · 2015: 9 · 2014: 5 · 2013: 3 · 2012: 3
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- ceftriaxone, gentamicin, streptococcal endocarditis, antibiotic monotherapy, combination antibiotic therapy, intravenous antibiotics, treatment efficacy, treatment safety, cardiac surgery
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Ceftriaxone, Cephalosporins, Drug Therapy, Combination, Endocarditis, Bacterial, Gentamicins, Humans, Middle Aged, Penicillins, Streptococcal Infections, Streptococcus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
